1.Iuliano, AD et al. (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285–1300.
2.Collaborators GBDI (2019) Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respiratory medicine 7, 69–89.
3.Beysard, N et al. (2018) Impact of the 2014–2015 influenza season on the activity of an academic emergency department. Internal and Emergency Medicine 13, 251–256.
4.Poon, CM et al. (2019) Management decision of hospital surge: assessing seasonal upsurge in inpatient medical bed occupancy rate among public acute hospitals in Hong Kong. QJM 112, 11–16.
5.Putri, W et al. (2018) Economic burden of seasonal influenza in the United States. Vaccine 36, 3960–3966.
6.Caini, S et al. (2018) Clinical characteristics and severity of influenza infections by virus type, subtype, and lineage: a systematic literature review. Influenza and Other Respiratory Viruses 12, 780–792.
7.Bedford, T et al. (2015) Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature 523, 217–220.
8.Skowronski, DM et al. (2017) Age-related differences in influenza B infection by lineage in a community-based sentinel system, 2010–2011 to 2015–2016, Canada. Journal of Infectious Diseases 216, 697–702.
9.Budd, AP et al. (2019) Birth cohort effects in influenza surveillance data: evidence that first influenza infection affects later influenza-associated illness. Journal of Infectious Diseases 220, 820–829.
10.Belongia, EA et al. (2016) Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infectious Diseases 16, 942–951.
11.Monto, AS et al. (2015) Antibody to influenza virus neuraminidase: an independent correlate of protection. Journal of Infectious Diseases 212, 1191–1199.
12.Zhu, H et al. (2018) Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017. Emerging Microbes and Infection 7, 23.
13.To, KK et al. (2010) Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgraduate Medical Journal 86, 515–521.
14.Zhang, AJ et al. (2011) High incidence of severe influenza among individuals over 50 years of age. Clinical and Vaccine Immunology 18, 1918–1924.
15.Cheng, VC et al. (2012) Two years after pandemic influenza A/2009/H1N1: what have we learned? Clinical Microbiology Reviews 25, 223–263.
16.Chan, KH et al. (2011) Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clinical and Vaccine Immunology 18, 867–873.
18.Shu, Y and McCauley, J (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. Eurosurveillance 22, pii: 30494.
19.Deorowicz, S, Debudaj-Grabysz, A and Gudys, A (2016) FAMSA: Fast and accurate multiple sequence alignment of huge protein families. Scientific Reports 6, 33964.
20.WHO Global Influenza Surveillance Network (2011) Manual for the Laboratory Diagnosis and Virological Surveillance of influenza. Geneva, Switzerland: WHO Global Influenza Surveillance Network.
21.Laurie, KL et al. (2015) International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE. Clinical and Vaccine Immunology 22, 957–964.
22.Wang, YD et al. (2009) Development and application of monoclonal antibodies-based antigen capture ELISA for detecting nucleocapsid protein of Influenza A virus. Guangdong Medical Journal 30, 703–705.
23.Hung, IF et al. (2016) Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial. Lancet Infectious Diseases 16, 209–218.
24.To, KK et al. (2012) High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clinical and Vaccine Immunology 19, 1012–1018.
25.Centre for Health Protection (2019) Local situation of influenza activity (as of Jan 9, 2019). Flu Express 16, 1–9.
28.Xie, H et al. (2017) Differential effects of prior influenza exposures on H3N2 cross-reactivity of human postvaccination sera. Clinical Infectious Diseases 65, 259–267.
32.Petrova, VN and Russell, CA (2018) The evolution of seasonal influenza viruses. Nature Reviews Microbiology 16, 60.
33.Skowronski, DM et al. (2016) A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 season. Clinical Infectious Diseases 63, 21–32.
34.Smith, DJ et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371–376.
35.Du, X et al. (2017) Evolution-informed forecasting of seasonal influenza A (H3N2). Science Translational Medicine 9, pii: eaan5325.
36.Neher, RA et al. (2016) Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. Proceedings of the National Academy of Sciences 113, E1701–E1709.
38.Zost, SJ et al. (2017) Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proceedings of the National Academy of Sciences 114, 12578–12583.